Press releases
Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.
2026
23 Oct 2026, 19:30
· The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful
· Graft and patient survival were 92% and 98%, respectively
· Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
20 Oct 2026, 19:00
20 Oct 2026, 17:05
· The IND submission marks an important milestone in advancing Hansa’s novel IgG-cleaving enzyme into clinical development in GBS.
1 Oct 2026, 08:00
Hansa is deploying Cradle’s end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease.
24 Sep 2026, 07:00 | Regulatory
22 Sep 2026, 17:30 | Regulatory